Fortrea Holdings Inc. Common Stock (FTRE)
Fortrea Holdings Inc. (FTRE) is a global contract research organization (CRO) that provides clinical development services to the biopharmaceutical and healthcare industries. The company offers a range of solutions including clinical trial management, data management, biostatistics, and regulatory consulting, supporting the development of new drugs and treatments. Fortrea is focused on delivering innovative and efficient clinical research services to accelerate pharmaceutical development worldwide.
Company News
Fortrea, a global contract research organization, will release its third quarter 2025 financial results on November 5, 2025, with a conference call scheduled at 8:00 am ET to review the results and conduct a Q&A session.
Fortrea Holdings reported Q2 2025 revenue of $710.3 million, beating analyst estimates by 12.5%. Despite positive revenue growth and improved adjusted earnings, the company faced challenges including a significant goodwill impairment and a book-to-bill ratio below target.
The Schall Law Firm is pursuing a class action lawsuit against Fortrea Holdings for allegedly making false and misleading statements about revenue projections, cost savings, and business model viability between July 2023 and February 2025.